Conferences - Results from #7520

ESMO 2018: Invited Discussant - Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma, from CheckMate 032 October 20, 2018

ESMO 2018: Pillars of an Effective Healthcare System in Europe Key Components of a Well-Functioning Healthcare System October 20, 2018

ESMO 2018: Invited Discussant - IMmotion151 and ATLAS Trial Results October 20, 2018

ESMO 2018: Prevention and Management in Long-Term Chronic Cancer Care: Pain Within the Cancer Trajectory October 20, 2018

ESMO 2018: PD-L1 Status and Clinical Outcomes to Cabozantinib, Sunitinib and Everolimus in Patients with Metastatic Clear-Cell RCC Treated on CABOSUN and METEOR Trials October 20, 2018

ESMO 2018: Brain Metastases Response to Nivolumab in Patients with Renal Cell Carcinoma: Prospective Analysis from the GETUG-AFU 26 (NIVOREN) Trial October 20, 2018

ESMO 2018: Molecular Correlates Differentiate Response to Atezolizumab plus Bevacizumab vs Sunitinib: Results From a Phase III Study IMmotion151 in Untreated mRCC October 20, 2018

ESMO 2018: Nivolumab Alone or in Combination With Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma October 20, 2018

ESMO 2018: Invited Discussant - Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG: Phase 2 Keynote-057 Trial October 20, 2018

ESMO 2018: Nivolumab in Combination with Iipilimumab Shows Promising Results in Patients with Advanced Form of Bladder Cancer October 20, 2018

ESMO 2018: Axitinib vs. Placebo in Patients at High Risk of Recurrent Renal Cell Carcinoma (RCC): ATLAS Trial Results October 20, 2018

ESMO 2018: Civic Participation: How Citizens Shape the Society they Live In October 20, 2018

ESMO 2018: Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG: Phase 2 Keynote-057 Trial October 20, 2018

ESMO 2018: When is a Cancer Patient Cured? October 20, 2018

ESMO 2018: The Right to be Forgotten - Access to Loan-Related Insurance for French Cancer Survivors October 20, 2018

ESMO 2018: Immunotherapy in Renal and Bladder Cancers October 20, 2018

ESMO 2018: Immune Therapies Going Adjuvant: Benefits Versus Risks: How Long Should We Treat Patients? October 20, 2018

ESMO 2018: Immune Therapies Going Adjuvant: Benefits Versus Risks: Side Effects October 20, 2018

ESMO 2018: Immune Therapies Going Adjuvant: Benefits Versus Risks: Introduction October 20, 2018

ESMO 2018: 12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer October 20, 2018

Page 377 of 622